Literature DB >> 24240108

HDM2 regulation by AURKA promotes cell survival in gastric cancer.

Vikas Sehdev1, Ahmed Katsha, Janet Arras, Dunfa Peng, Mohammed Soutto, Jeffrey Ecsedy, Alexander Zaika, Abbes Belkhiri, Wael El-Rifai.   

Abstract

PURPOSE: Suppression of P53 (tumor protein 53) transcriptional function mediates poor therapeutic response in patients with cancer. Aurora kinase A (AURKA) and human double minute 2 (HDM2) are negative regulators of P53. Herein, we examined the role of AURKA in regulating HDM2 and its subsequent effects on P53 apoptotic function in gastric cancer. EXPERIMENTAL
DESIGN: Primary tumors and in vitro gastric cancer cell models with overexpression or knockdown of AURKA were used. The role of AURKA in regulating HDM2 and cell survival coupled with P53 expression and activity were investigated.
RESULTS: Overexpression of AURKA enhanced the HDM2 protein level; conversely, knockdown of endogenous AURKA decreased expression of HDM2 in AGS and SNU-1 cells. Dual co-immunoprecipitation assay data indicated that AURKA was associated with HDM2 in a protein complex. The in vitro kinase assay using recombinant AURKA and HDM2 proteins followed by co-immunoprecipitation revealed that AURKA directly interacts and phosphorylates HDM2 protein in vitro. The activation of HDM2 by AURKA led to induction of P53 ubiquitination and attenuation of cisplatin-induced activation of P53 in gastric cancer cells. Inhibition of AURKA using an investigational small-molecule specific inhibitor, alisertib, decreased the HDM2 protein level and induced P53 transcriptional activity. These effects markedly decreased cell survival in vitro and xenograft tumor growth in vivo. Notably, analysis of immunohistochemistry on tissue microarrays revealed significant overexpression of AURKA and HDM2 in human gastric cancer samples (P < 0.05).
CONCLUSION: Collectively, our novel findings indicate that AURKA promotes tumor growth and cell survival through regulation of HDM2-induced ubiquitination and inhibition of P53. Clin Cancer Res; 20(1); 76-86. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24240108      PMCID: PMC3947328          DOI: 10.1158/1078-0432.CCR-13-1187

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

2.  Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans.

Authors:  Mohammed Soutto; Abbes Belkhiri; M Blanca Piazuelo; Barbara G Schneider; Dunfa Peng; Aixiang Jiang; M Kay Washington; Yasin Kokoye; Sheila E Crowe; Alexander Zaika; Pelayo Correa; Richard M Peek; Wael El-Rifai
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

3.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

4.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

5.  Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression.

Authors:  Zhengyu Fang; Yi Xiong; Jiana Li; Li Liu; Manhui Li; Chao Zhang; Wei Zhang; Jun Wan
Journal:  Med Oncol       Date:  2010-06-29       Impact factor: 3.064

6.  Aurora kinase A in Barrett's carcinogenesis.

Authors:  Massimo Rugge; Matteo Fassan; Giovanni Zaninotto; Marco Pizzi; Luciano Giacomelli; Giorgio Battaglia; Christian Rizzetto; Paola Parente; Ermanno Ancona
Journal:  Hum Pathol       Date:  2010-07-24       Impact factor: 3.466

7.  Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.

Authors:  Kazuya Sumi; Kenji Tago; Tadashi Kasahara; Megumi Funakoshi-Tago
Journal:  FEBS Lett       Date:  2011-05-08       Impact factor: 4.124

8.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

9.  Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).

Authors:  James Cronin; Elizabeth McAdam; Antonios Danikas; Chris Tselepis; Paul Griffiths; John Baxter; Linzi Thomas; James Manson; Gareth Jenkins
Journal:  Am J Gastroenterol       Date:  2010-12-14       Impact factor: 10.864

Review 10.  The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.

Authors:  C Matuschek; Edwin Bölke; M Peiper; W T Knoefel; W Budach; A Erhardt; A Scherer; P A Gerber; B A Buhren; N Gattermann; S E Baldus; E Rusnak; V Shukla; K Orth
Journal:  Eur J Med Res       Date:  2011-06-21       Impact factor: 2.175

View more
  35 in total

1.  AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers.

Authors:  Ahmed Katsha; Janet Arras; Mohammed Soutto; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Oncol       Date:  2014-06-03       Impact factor: 6.603

2.  Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.

Authors:  Ahmed Katsha; Lihong Wang; Janet Arras; Omar M Omar; Jeffrey Ecsedy; Abbes Belkhiri; Wael El-Rifai
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

3.  Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Authors:  Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin
Journal:  Invest New Drugs       Date:  2018-09-06       Impact factor: 3.850

4.  AURKA is a predictor of chemotherapy response and prognosis for patients with advanced oral squamous cell carcinoma.

Authors:  Yadong Li; Jinsong Zhang
Journal:  Tumour Biol       Date:  2014-12-30

5.  Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma.

Authors:  Po Zhao; Yali Lu; Lin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Screening a novel six critical gene-based system of diagnostic and prognostic biomarkers in prostate adenocarcinoma patients with different clinical variables.

Authors:  Hadia Munir; Fawad Ahmad; Sajid Ullah; Saeedah Musaed Almutairi; Samra Asghar; Tehmina Siddique; Mostafa A Abdel-Maksoud; Rabab Ahmed Rasheed; Fatma Alzahraa A Elkhamisy; Mohammed Aufy; Hamid Yaz
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

7.  Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Authors:  Lihong Wang-Bishop; Zheng Chen; Ahmed Gomaa; Albert Craig Lockhart; Safia Salaria; Jialiang Wang; Keeli B Lewis; Jeffrey Ecsedy; Kay Washington; Robert Daniel Beauchamp; Wael El-Rifai
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

Review 8.  Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

Authors:  Salma K Jabbour; Terence M Williams; Mutlay Sayan; Eric D Miller; Jaffer A Ajani; Andrew C Chang; Norman Coleman; Wael El-Rifai; Michael Haddock; David Ilson; Daniel Jamorabo; Charles Kunos; Steven Lin; Geoffrey Liu; Pataje G Prasanna; Anil K Rustgi; Rosemary Wong; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

Review 9.  Advances in targeted therapies and new promising targets in esophageal cancer.

Authors:  Abbes Belkhiri; Wael El-Rifai
Journal:  Oncotarget       Date:  2015-01-30

10.  Identification of the hub genes and prognostic indicators of gastric cancer and correlation of indicators with tumor-infiltrating immune cell levels.

Authors:  Yun Ji; Lu Gao; Can Zhang; Xu Sun; Liping Dai; Zhenyu Ji; Jianying Zhang; Zhida Zhang; Wei Cao; Yang Zhao; Liguo Zhang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.